Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)

Vittorio Pengo, Luciano Crippa, Anna Falanga, Guido Finazzi, Francesco Marongiu, Gualtiero Palareti, Daniela Poli, Sophie Testa, Eros Tiraferri, Alberto Tosetto, Armando Tripodi, Cesare Manotti

Research output: Contribution to journalArticlepeer-review

Abstract

Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.

Original languageEnglish
Pages (from-to)868-876
Number of pages9
JournalThrombosis and Haemostasis
Volume106
Issue number5
DOIs
Publication statusPublished - Nov 2011

Keywords

  • Clinical trials
  • Heart
  • Oral anticoagulants
  • Prevention

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)'. Together they form a unique fingerprint.

Cite this